Impax Investors' Drug Price-Fixing Suit Revived By 9th Circ.

Law360 (January 11, 2021, 10:43 PM EST) -- The Ninth Circuit partially revived a shareholder suit Monday alleging generic-drug maker Impax Laboratories Inc. participated in a price-fixing scheme that led to a dip in the company's stock price, finding that the investors sufficiently alleged the cause of some of their economic losses but missed the mark on others.

In a sparse nine-page opinion, a three-judge panel found that the California district court erred when it ruled that the investors hadn't shown they suffered their claimed economic losses as a result of the alleged price-fixing conspiracy, finding that the investors' allegations regarding May and August 2015 earnings misses are enough...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!